|Articles|February 15, 2002

BioPharm International

  • BioPharm International-02-01-2002
  • Volume 15
  • Issue 2

Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

Author(s)Tom Brody

By Tom Brody, DNAX Research Institute, pp. 38-42. Early sale or offers to sell an invention may result in the rejection of a patent application under 35 U.S.C. 102(b). Such a rejection is called "the on-sale bar," and it permanently prevents patenting of an invention.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.